FDA's Buffy Coat Blood Bag Upgrade: Safer Transfusions Ahead
Published Date: 9/17/2026
Notice
Summary
The FDA just released final guidance to help companies make better blood collection and storage systems using the buffy coat method. This affects manufacturers who create blood bags and related products, aiming to improve safety and quality for blood transfusions. The new rules are effective now, so companies should update their products and submissions to meet these recommendations, potentially saving time and money in the long run.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-19079, Agency Information Collection Activities: Proposed Collection; Comment Request
The Substance Abuse and Mental Health Services Administration (SAMHSA) is planning the 2027 National Survey on Drug Use and Health, which asks people 12 and older about drug use and health. They’re keeping the survey mostly the same but won’t include U.S. territories yet, and they’ll keep paying participants $30 for completing it. SAMHSA wants your feedback on how to make the survey better and easier for people to complete.
Next: 2026-19081, Notice of Determinations; Culturally Significant Objects Being Imported for Exhibition-Determinations: “Rembrandt's Lions: Art and Exile in the Dutch Republic” Exhibition
The U.S. government has approved the temporary import of important cultural objects for the exhibition “Rembrandt's Lions: Art and Exile in the Dutch Republic” at The Morgan Library & Museum in New York. This means these valuable artworks can be shown in the U.S. because it benefits the public and honors cultural heritage. The exhibition might also travel to other locations, bringing art and history to more people without any direct cost impact.